Clinical trials
Lymphangioleiomyomatosis clinical trials
Below are recruiting lymphangioleiomyomatosis clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06405997Recruiting
Study of LAM: genes and symptoms
This study looks at the genes and physical traits of people with lymphangioleiomyomatosis (LAM), a rare lung disease that causes cysts. It aims to help better understand and treat LAM.
TaipeiAges 18 years+ - NCT06889168RecruitingPhase 1
Long-term safety of imatinib for LAM
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
New York, New YorkAges 18–64 - NCT06160310Recruiting
TSC & LAM Pregnancy Registry Study
This study is a registry that gathers information from pregnant women with Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM), as well as infants born to them. The goal is to better understand how these conditions affect pregnancy and the baby's health.
Cincinnati, OhioAges Any age - NCT07304856Recruiting
Studying lung involvement in women with LAM or TSC
This trial examines tiny particles called extracellular vesicles from your blood to see if they can help doctors understand lung problems in women with lymphangioleiomyomatosis (LAM) or tuberous sclerosis complex (TSC). It may help find new ways to track the disease without invasive tests.
Milan, MilanoAges 18–80 - NCT00001465Recruiting
Understanding how lymphangioleiomyomatosis affects the lungs
This research study examines how a rare lung disease called lymphangioleiomyomatosis (LAM) develops and progresses. Researchers will study patients with LAM and healthy volunteers to better understand the disease and potentially improve treatment options.
Bethesda, MarylandAges 16–100 - NCT01484236Recruiting
Lymphangioleiomyomatosis patient registry in France
This trial is a national registry that collects information about people with lymphangioleiomyomatosis to better understand the condition and care over time. It may help by contributing real-world data from patients with sporadic disease or related tuberous sclerosis.
LyonAges 18 years+ - NCT01799538RecruitingPhase 1/Phase 2
Inhaled albuterol for lung disease LAM
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
Bethesda, MarylandAges 18–100 - NCT03193892Recruiting
National registry for women with lymphangioleiomyomatosis
This trial is a national health registry that collects medical information from women with lymphangioleiomyomatosis (LAM), a rare lung condition. It helps researchers better understand who has LAM and what their health looks like over time.
Beijing, Beijing MunicipalityAges Any age - NCT05676099Recruiting
TSC or LAM blood and health information registry
This study sets up a database and collection of “biosamples” (like blood or other body samples) from people with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). The goal is to better understand how these conditions change over time and support future research.
Birmingham, AlabamaAges Any age - NCT02432560Recruiting
Testing sirolimus for long-term treatment of LAM
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Stanford, CaliforniaAges 18 years+ - NCT05727852Enrolling by invitation
Breath and heart tests to study lung disease stiffness
This study uses breath analysis and heart/electrical heart testing to look at how stiff the arteries are in people with long-term lung conditions. It may help researchers better understand lung disease effects on the cardiovascular system.
MoscowAges 18 years+
Hear when a new Lymphangioleiomyomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Lymphangioleiomyomatosis trials by city
Studies with a site in or near these metro areas.
Lymphangioleiomyomatosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for lymphangioleiomyomatosis?
- Yes. Clin2 currently lists 11 recruiting lymphangioleiomyomatosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphangioleiomyomatosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphangioleiomyomatosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.